MUNICH, GERMANY--(MARKET WIRE)--Jul 5, 2006 -- Origenis GmbH today announced that it has extended the research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis’ compound design and synthesis capabilities with Alcon’s applied biology expertise, screening capabilities and development expertise.
